{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:20Z","timestamp":1792099580817,"version":"4.4.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin\u2019s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant eligible patients, or less intensive chemotherapy for the less fit (and transplant-ineligible) patients. Patients eventually relapse with a progressive clinical course. Numerous therapeutic approaches have emerged over the last few years which have significantly changed the treatment landscape of MCL. These therapies consist of targeted approaches such as BTK and BCL2 inhibitors that provide durable therapeutic responses. However, the optimum combination and sequencing of these therapies is unclear and is currently investigated in several ongoing studies. Furthermore, cellular therapies such as chimeric antigen receptor (CAR) T cells and bispecific T cell engager (BiTe) antibodies have shown impressive results and will likely shape treatment approaches in relapsed MCL, especially after failure with BTK inhibitors. Herein, we provide a comprehensive review of past and ongoing studies that will likely significantly impact our approach to MCL treatment in both the frontline (for transplant eligible and ineligible patients) as well as in the relapsed setting. We present the most up to date results from these studies as well as perspectives on future studies in MCL.<\/jats:p>","DOI":"10.1186\/s13045-020-00914-1","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T13:03:53Z","timestamp":1592399033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Emerging therapies in mantle cell lymphoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Walter","family":"Hanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"issue":"20","key":"914_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"5","key":"914_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.14699","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703\u20136.","journal-title":"Br J Haematol"},{"issue":"2","key":"914_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365.","journal-title":"Blood."},{"issue":"17","key":"914_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310.","journal-title":"Blood."},{"issue":"1","key":"914_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"issue":"6","key":"914_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. 2014;166(6):849\u201361.","journal-title":"Br J Haematol"},{"issue":"8","key":"914_CR7","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052\u201364.","journal-title":"J Clin Invest"},{"issue":"6","key":"914_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood."},{"issue":"21","key":"914_CR9","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1182\/blood.V124.21.4453.4453","volume":"124","author":"M Wang","year":"2014","unstructured":"Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2\u2009years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. Blood. 2014;124(21):4453.","journal-title":"Blood"},{"issue":"10020","key":"914_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770\u20138.","journal-title":"Lancet."},{"issue":"10121","key":"914_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet."},{"issue":"11","key":"914_CR12","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019;33(11):2762\u20136.","journal-title":"Leukemia."},{"issue":"Supplement 1","key":"914_CR13","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1182\/blood-2018-99-110327","volume":"132","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Long-term follow-up of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2018;132(Supplement 1):2876.","journal-title":"Blood"},{"issue":"Supplement 1","key":"914_CR14","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1182\/blood-2018-99-117224","volume":"132","author":"CS Tam","year":"2018","unstructured":"Tam CS, Wang M, Simpson D, Opat S, Cull G, Munoz J, et al. Updated safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma. Blood. 2018;132(Supplement 1):1592.","journal-title":"Blood"},{"issue":"Supplement 1","key":"914_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","volume":"132","author":"Y Song","year":"2018","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial. Blood. 2018;132(Supplement 1):148.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2019-127509","volume":"134","author":"AR Mato","year":"2019","unstructured":"Mato AR, Flinn IW, Pagel JM, Brown JR, Cheah CY, Coombs CC, et al. Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor. Blood. 2019;134(Supplement_1):501.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR17","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2019-127260","volume":"134","author":"J Woyach","year":"2019","unstructured":"Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134(Supplement_1):4298.","journal-title":"Blood"},{"issue":"3","key":"914_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430\u20138.","journal-title":"Br J Haematol"},{"key":"914_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"914_CR20","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340.","journal-title":"J Med Chem"},{"issue":"Supplement_1","key":"914_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2019-125394","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the sequoia (BGB-3111-304) trial. Blood. 2019;134(Supplement_1):499.","journal-title":"Blood"},{"key":"914_CR22","doi-asserted-by":"crossref","unstructured":"Tam COS, Zhu J, Cull G, Gottlieb D, Li J, Marlton P, Qiu L, Roberts A, Seymour J, Simpson D, Song Y, Yang H, Du C, Feng S, Ji M, Lin L, Novotny W, Wang A, Trotman J. Pooled analysis of safety data from monotherapy studies of the bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies. Eur Hematol Assoc. 2018.","DOI":"10.1097\/01.HS9.0000562920.26603.5b"},{"issue":"12","key":"914_CR23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u201363.","journal-title":"Blood."},{"issue":"4","key":"914_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study. Hematol Oncol. 2017;35(4):528\u201335.","journal-title":"Hematol Oncol"},{"issue":"4","key":"914_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578\u201387.","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"914_CR26","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1182\/blood-2019-126114","volume":"134","author":"EB Gomez","year":"2019","unstructured":"Gomez EB, Isabel L, Rosendahal MS, Rothenberg SM, Andrews SW, Brandhuber BJ. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Blood. 2019;134(Supplement_1):4644.","journal-title":"Blood"},{"issue":"10","key":"914_CR27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","volume":"8","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation. Cancer Discov. 2018;8(10):1300\u201315.","journal-title":"Cancer Discov"},{"issue":"13","key":"914_CR28","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-11-3152","volume":"18","author":"C Deng","year":"2012","unstructured":"Deng C, Lee S, O'Connor OA. New strategies in the treatment of mantle cell lymphoma. Clin Cancer Res. 2012;18(13):3499\u2013508.","journal-title":"Clin Cancer Res"},{"key":"914_CR29","unstructured":"Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, et al. The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica. 2019."},{"issue":"8","key":"914_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"914_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/path.1254","volume":"199","author":"JD Khoury","year":"2003","unstructured":"Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2003;199(1):90\u20137.","journal-title":"J Pathol"},{"issue":"9","key":"914_CR32","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41388-019-1122-x","volume":"39","author":"MA Dengler","year":"2020","unstructured":"Dengler MA, Teh CE, Thijssen R, Gangoda L, Lan P, Herold MJ, et al. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene. 2020;39(9):2009\u201323.","journal-title":"Oncogene."},{"issue":"14","key":"914_CR33","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","volume":"25","author":"D Prukova","year":"2019","unstructured":"Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25(14):4455\u201365.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"914_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88\u201395.","journal-title":"J Immunol"},{"issue":"1","key":"914_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107(1):257\u201364.","journal-title":"Blood."},{"issue":"30","key":"914_CR36","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"914_CR37","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520\u20135.","journal-title":"Ann Oncol"},{"issue":"11","key":"914_CR38","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","volume":"12","author":"L Zhang","year":"2013","unstructured":"Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, et al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013;12(11):2494\u2013504.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"914_CR39","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557\u201369.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"914_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bjh.15107","volume":"184","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Badillo M, Romaguera J, Wang M. A phase II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma. Br J Haematol. 2019;184(3):460\u20132.","journal-title":"Br J Haematol"},{"issue":"24","key":"914_CR41","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","volume":"73","author":"K Song","year":"2013","unstructured":"Song K, Herzog BH, Sheng M, Fu J, McDaniel JM, Chen H, et al. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013;73(24):7254\u201364.","journal-title":"Cancer Res"},{"issue":"1","key":"914_CR42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36\u201345.","journal-title":"Br J Haematol"},{"issue":"9","key":"914_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84(9):553\u20139.","journal-title":"Am J Hematol"},{"issue":"5","key":"914_CR44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/his.13935","volume":"75","author":"G Petrakis","year":"2019","unstructured":"Petrakis G, Veloza L, Clot G, Gine E, Gonzalez-Farre B, Navarro A, et al. Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma. Histopathology. 2019;75(5):704\u201314.","journal-title":"Histopathology."},{"issue":"3","key":"914_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344\u20139.","journal-title":"Br J Haematol"},{"issue":"11","key":"914_CR46","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24(11):2892\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"914_CR47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjh.12449","volume":"162","author":"JM Vose","year":"2013","unstructured":"Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013;162(5):639\u201347.","journal-title":"Br J Haematol"},{"issue":"29","key":"914_CR48","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"914_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","volume":"17","author":"M Trneny","year":"2016","unstructured":"Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319\u201331.","journal-title":"Lancet Oncol"},{"issue":"3","key":"914_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2040620714532124","volume":"5","author":"M Desai","year":"2014","unstructured":"Desai M, Newberry K, Ou Z, Wang M, Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol. 2014;5(3):91\u2013101.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"914_CR51","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bjh.13132","volume":"168","author":"DA Heinrich","year":"2015","unstructured":"Heinrich DA, Weinkauf M, Hutter G, Zimmermann Y, Jurinovic V, Hiddemann W, et al. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br J Haematol. 2015;168(4):606\u201310.","journal-title":"Br J Haematol"},{"issue":"23","key":"914_CR52","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"914_CR53","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","volume":"194","author":"U Klein","year":"2001","unstructured":"Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625\u201338.","journal-title":"J Exp Med"},{"issue":"11","key":"914_CR54","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","volume":"194","author":"A Rosenwald","year":"2001","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639\u201347.","journal-title":"J Exp Med"},{"issue":"1","key":"914_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hon.948","volume":"29","author":"G Barna","year":"2011","unstructured":"Barna G, Mihalik R, Timar B, Tombol J, Csende Z, Sebestyen A, et al. ROR1 expression is not a unique marker of CLL. Hematol Oncol. 2011;29(1):17\u201321.","journal-title":"Hematol Oncol"},{"issue":"2","key":"914_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1172\/JCI83535","volume":"126","author":"J Yu","year":"2016","unstructured":"Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585\u201398.","journal-title":"J Clin Invest"},{"issue":"37","key":"914_CR57","doi-asserted-by":"publisher","first-page":"24731","DOI":"10.18632\/oncotarget.25340","volume":"9","author":"J Yu","year":"2018","unstructured":"Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF 2nd, et al. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018;9(37):24731\u20136.","journal-title":"Oncotarget."},{"issue":"6","key":"914_CR58","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22(6):951\u20139 e3.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"914_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bjh.13099","volume":"168","author":"JM Pagel","year":"2015","unstructured":"Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR() therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015;168(1):38\u201345.","journal-title":"Br J Haematol"},{"issue":"26","key":"914_CR60","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1182\/blood-2011-06-363879","volume":"118","author":"L Alinari","year":"2011","unstructured":"Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011;118(26):6893\u2013903.","journal-title":"Blood."},{"issue":"11","key":"914_CR61","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3109\/10428194.2015.1028052","volume":"56","author":"P Martin","year":"2015","unstructured":"Martin P, Furman RR, Rutherford S, Ruan J, Ely S, Greenberg J, et al. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leuk Lymphoma. 2015;56(11):3065\u201370.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"914_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood.V81.1.84.84","volume":"81","author":"M Okazaki","year":"1993","unstructured":"Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia\/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood. 1993;81(1):84\u201394.","journal-title":"Blood."},{"issue":"2","key":"914_CR63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365.","journal-title":"J Clin Oncol"},{"issue":"5","key":"914_CR64","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.12862","volume":"98","author":"S Thota","year":"2017","unstructured":"Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425\u201334.","journal-title":"Eur J Haematol"},{"issue":"4","key":"914_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/bjh.14820","volume":"182","author":"NH Dang","year":"2018","unstructured":"Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182(4):583\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"914_CR66","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254\u2013e65.","journal-title":"Lancet Haematol"},{"issue":"13 Supplement","key":"914_CR67","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1538-7445.AM2018-835","volume":"78","author":"AP Maclaren","year":"2018","unstructured":"Maclaren AP, Levin N, Lowman H. Abstract 835: TRPH-222, a novel anti-CD22 antibody drug conjugate (ADC), has significant anti-tumor activity in NHL xenografts and reduces B cells in monkeys. Cancer Res. 2018;78(13 Supplement):835.","journal-title":"Cancer Res"},{"issue":"23","key":"914_CR68","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A phase I study of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986\u201394.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"914_CR69","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","volume":"103","author":"M Trneny","year":"2018","unstructured":"Trneny M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103(8):1351\u20138.","journal-title":"Haematologica."},{"issue":"5","key":"914_CR70","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.13992","volume":"173","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722\u201330.","journal-title":"Br J Haematol"},{"issue":"23","key":"914_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood.V126.23.182.182","volume":"126","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Fanale MA, Shah BD, Advani RH, Chen R, Kim S, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed\/refactory B-lineage non-Hodgkin lymphoma. Blood. 2015;126(23):182.","journal-title":"Blood"},{"issue":"20","key":"914_CR72","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","volume":"122","author":"J Deckert","year":"2013","unstructured":"Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500\u201310.","journal-title":"Blood."},{"issue":"5","key":"914_CR73","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","volume":"36","author":"A Stathis","year":"2018","unstructured":"Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investig New Drugs. 2018;36(5):869\u201376.","journal-title":"Investig New Drugs"},{"issue":"23","key":"914_CR74","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1182\/blood.V126.23.3976.3976","volume":"126","author":"A Sawas","year":"2015","unstructured":"Sawas A, Savage KJ, Perez R, Advani RH, Butturini A, Lackey J, et al. A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim Results. Blood. 2015;126(23):3976.","journal-title":"Blood"},{"issue":"1","key":"914_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","volume":"17","author":"ML Wang","year":"2016","unstructured":"Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48\u201356.","journal-title":"Lancet Oncol"},{"issue":"13","key":"914_CR76","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"914_CR77","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood-2019-126619","volume":"134","author":"SM Handunnetti","year":"2019","unstructured":"Handunnetti SM, Anderson MA, Burbury K, Hicks RJ, Birbirsa B, Bressel M, et al. Three year update of the phase II ABT-199 (venetoclax) and Ibrutinib in mantle cell lymphoma (AIM) study. Blood. 2019;134(Supplement_1):756.","journal-title":"Blood"},{"issue":"Supplement 1","key":"914_CR78","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1182\/blood-2018-99-113777","volume":"132","author":"S Le Gouill","year":"2018","unstructured":"Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas R-O, Milpied N-J, et al. Ibrutinib plus obinutuzumab and venetoclax in relapsed\/refractory mantle cells lymphoma patients, results of the OASIS phase i clinical trial. Blood. 2018;132(Supplement 1):4158.","journal-title":"Blood"},{"issue":"7","key":"914_CR79","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012;13(7):716\u201323.","journal-title":"Lancet Oncol"},{"issue":"8","key":"914_CR80","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","volume":"21","author":"EA Chong","year":"2015","unstructured":"Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21(8):1835\u201342.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"914_CR81","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M, Raty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109\u2013e16.","journal-title":"Lancet Haematol"},{"issue":"11","key":"914_CR82","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","volume":"133","author":"P Martin","year":"2019","unstructured":"Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201\u20134.","journal-title":"Blood."},{"issue":"5","key":"914_CR83","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.13149","volume":"168","author":"X Zhao","year":"2015","unstructured":"Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168(5):765\u20138.","journal-title":"Br J Haematol"},{"issue":"24","key":"914_CR84","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128(24):2808\u201318.","journal-title":"Blood."},{"issue":"Supplement_1","key":"914_CR85","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2019-125681","volume":"134","author":"S Le Gouill","year":"2019","unstructured":"Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Gastinne T, et al. Ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma patients. Blood. 2019;134(Supplement_1):1530.","journal-title":"Blood"},{"key":"914_CR86","doi-asserted-by":"crossref","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020.","DOI":"10.1111\/bjh.16416"},{"key":"914_CR87","doi-asserted-by":"crossref","unstructured":"Lee C, Huang X, Di Liberto M, Martin P, Chen-Kiang S. Targeting CDK4\/6 in mantle cell lymphoma. Ann Lymphoma. 2020;4.","DOI":"10.21037\/aol.2019.12.01"},{"issue":"20","key":"914_CR88","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597\u2013607.","journal-title":"Blood."},{"issue":"12","key":"914_CR89","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4161\/cc.24928","volume":"12","author":"D Chiron","year":"2013","unstructured":"Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, et al. Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle. 2013;12(12):1892\u2013900.","journal-title":"Cell Cycle"},{"issue":"1","key":"914_CR90","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1038\/s41598-017-18368-w","volume":"7","author":"J Dey","year":"2017","unstructured":"Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition. Sci Rep. 2017;7(1):18007.","journal-title":"Sci Rep"},{"issue":"14","key":"914_CR91","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"26","key":"914_CR92","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"914_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"914_CR94","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","volume":"57","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Bargou R. Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57(5):1021\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"914_CR95","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase i study. J Clin Oncol. 2016;34(10):1104\u201311.","journal-title":"J Clin Oncol"},{"issue":"16","key":"914_CR96","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","volume":"3","author":"V Dufner","year":"2019","unstructured":"Dufner V, Sayehli CM, Chatterjee M, Hummel HD, Gelbrich G, Bargou RC, et al. Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3(16):2491\u20138.","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"914_CR97","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bartlett NL, Assouline S, Yoon S-S, Bosch F, Sehn LH, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(Supplement_1):6.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR98","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2019-122451","volume":"134","author":"R Bannerji","year":"2019","unstructured":"Bannerji R, Allan JN, Arnason JE, Brown JR, Advani RH, Barnes JA, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(Supplement_1):762.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR99","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2019-121460","volume":"134","author":"P Lugtenburg","year":"2019","unstructured":"Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, et al. First-in-human, phase 1\/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody\u00ae-CD3 \u00d7 CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019;134(Supplement_1):758.","journal-title":"Blood"},{"key":"914_CR100","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.","journal-title":"EBioMedicine."},{"issue":"12","key":"914_CR101","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.31361","volume":"124","author":"JE Romaguera","year":"2018","unstructured":"Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, et al. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018;124(12):2561\u20139.","journal-title":"Cancer."},{"issue":"4","key":"914_CR102","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.bbmt.2014.01.004","volume":"20","author":"BM William","year":"2014","unstructured":"William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, et al. Phase I\/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biol Blood Marrow Transplant. 2014;20(4):536\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"914_CR103","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/blood-2018-99-112655","volume":"132","author":"LD Kaplan","year":"2018","unstructured":"Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, et al. Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8\u2009year follow up of CALGB 50403 (Alliance). Blood. 2018;132(Supplement 1):146.","journal-title":"Blood"},{"issue":"23","key":"914_CR104","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood.V126.23.339.339","volume":"126","author":"JK Doorduijn","year":"2015","unstructured":"Doorduijn JK, Minnema MC, Kersten MJ, Lugtenburg PJ, Schipperus MR, van Marwijk Kooy M, et al. Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study. Blood. 2015;126(23):339.","journal-title":"Blood"},{"key":"914_CR105","doi-asserted-by":"crossref","unstructured":"Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Bohmer LH, Minnema MC, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020.","DOI":"10.1111\/bjh.16567"},{"issue":"19","key":"914_CR106","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","volume":"132","author":"J Ruan","year":"2018","unstructured":"Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016\u201325.","journal-title":"Blood."},{"issue":"8","key":"914_CR107","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMc1514201","volume":"374","author":"J Ruan","year":"2016","unstructured":"Ruan J, Leonard JP. Lenalidomide plus rituximab for mantle-cell lymphoma. N Engl J Med. 2016;374(8):793.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"914_CR108","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2019-127863","volume":"134","author":"M Dreyling","year":"2019","unstructured":"Dreyling M, Ladetto M, Doorduijn JK, Gine E, Jerkeman M, Mey U, et al. Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma - a randomized European MCL Network Trial. Blood. 2019;134(Supplement_1):2816.","journal-title":"Blood"},{"issue":"S2","key":"914_CR109","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hon.12_2629","volume":"37","author":"M Wang","year":"2019","unstructured":"Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, et al. Ibrutinib with rituximab (IR) and short course R-HYPERCVAD\/MTX is very efficacious in previously untreated young PTS with mantle cell lymphoma (MCL). Hematol Oncol. 2019;37(S2):42\u20133.","journal-title":"Hematol Oncol"},{"issue":"23","key":"914_CR110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/blood.V126.23.337.337","volume":"126","author":"LD Kaplan","year":"2015","unstructured":"Kaplan LD, Jung S-H, Stock W, Bartlett NL, Pitcher B, Byrd JC, et al. Bortezomib maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403. Blood. 2015;126(23):337.","journal-title":"Blood"},{"issue":"10","key":"914_CR111","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934\u201347.","journal-title":"N Engl J Med"},{"issue":"19","key":"914_CR112","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"914_CR113","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","volume":"128","author":"A Albertsson-Lindblad","year":"2016","unstructured":"Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, et al. Lenalidomide-bendamustine-rituximab in patients older than 65\u2009years with untreated mantle cell lymphoma. Blood. 2016;128(14):1814\u201320.","journal-title":"Blood."},{"issue":"2","key":"914_CR114","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","volume":"125","author":"K Maddocks","year":"2015","unstructured":"Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, et al. A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma. Blood. 2015;125(2):242\u20138.","journal-title":"Blood."},{"issue":"9","key":"914_CR115","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","volume":"29","author":"S de Vos","year":"2018","unstructured":"de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932\u20138.","journal-title":"Ann Oncol"},{"issue":"22","key":"914_CR116","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","volume":"128","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Topp MS, Yuen SL, Rusconi C, Fleury I, Pro B, et al. Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data. Blood. 2016;128(22):617.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR117","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1182\/blood-2019-122759","volume":"134","author":"CA Portell","year":"2019","unstructured":"Portell CA, Bennani NN, Jegede O, Naik S, Parsons BM, Patel PP, et al. Bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60\u2009years of age (PrE0405): a phase II study. Blood. 2019;134(Supplement_1):5243.","journal-title":"Blood"},{"issue":"Supplement_1","key":"914_CR118","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2019-125800","volume":"134","author":"P Jain","year":"2019","unstructured":"Jain P, Lee HJ, Steiner RE, Hagemeister FB, Samaniego F, Westin JR, et al. Frontline treatment with ibrutinib with rituximab (IR) combination is highly effective in elderly (\u226565\u2009years) patients with mantle cell lymphoma (MCL) - results from a phase ii trial. Blood. 2019;134(Supplement_1):3988.","journal-title":"Blood"},{"issue":"6","key":"914_CR119","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37(6):471\u201380.","journal-title":"J Clin Oncol"},{"issue":"16","key":"914_CR120","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215\u201323.","journal-title":"Blood."},{"issue":"Supplement 1","key":"914_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood-2018-99-112573","volume":"132","author":"R Lakhotia","year":"2018","unstructured":"Lakhotia R, Melani C, Pittaluga S, Dunleavy K, Saba NS, Lucas AN, et al. Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma. Blood. 2018;132(Supplement 1):147.","journal-title":"Blood"},{"issue":"Supplement 1","key":"914_CR122","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2018-99-114442","volume":"132","author":"S Ferrero","year":"2018","unstructured":"Ferrero S, Daniela B, Lo Schirico M, Evangelista A, Cifaratti A, Drandi D, et al. Comprehensive minimal residual disease (MRD) analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial for younger patients with mantle cell lymphoma: a kinetic model ensures a more refined risk stratification. Blood. 2018;132(Supplement 1):920.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:37:52Z","timestamp":1696253872000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00914-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WH has no relevant COI. NE has received honoraria from the Pharmacyclics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}